Latest Headlines

Latest Headlines

Quest Diagnostics snags Celera in $344M buyout

Quest Diagnostics is snapping up Celera--along with its expertise in genetics and biomarkers--for $344 million in cash. "Our discovery and validation of new biomarkers has exceeded our capacity...

Celgene strikes $2.9B deal to acquire Abraxis

With an eye to burnishing its oncology rep and its already sizable revenue, Celgene has struck a deal to buy Abraxis BioScience for cash and stock totaling $2.9 billion. The buyout gives Celgene...

Oracle buys Phase Forward for $685M

Oracle announced today that it's purchasing Phase Forward for $17.00 per share in cash, or about $685 million. The deal, which is expected to close in mid-2010, represents a 30 percent premium over...

Abraxis mulls sale of company

Abraxis Bioscience has retained Goldman Sachs and Lazard to explore the possible sale of the company, sources tell dealReporter. The rumored deal talks follow the release of data last month showing...

Biotech's value creation chain starts with research link

What's the real value of drug research? The Scientist analyzed the payoffs earned by success in the drug development field these days. With IPOs largely shelved this year--only one biotech has pulled
  • « first
  • ‹ previous
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247